News
Cigna's Evernorth business caps GLP-1 drug copays at $200 or less, aiming to boost affordability for patients and cut costs for health plan sponsors. The Cigna Group (NYSE:CI)’s Evernorth ...
GoodRx says that with the support of a healthcare team, a clear transition plan, and a few cost-saving tools, you can make ...
A bipartisan bill soon to be introduced in the state Legislature seeks to decrease the cost of GLP-1 drugs in Pennsylvania.
Omada Health closed 21% higher in its Nasdaq debut after raising $150 million. Backed by strong growth and GLP-1 momentum, ...
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated ...
People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, including Alzheimer's, but an increase in some other conditions like kidney ...
As earlier outlined, short-term studies in animals and humans have shown GLP-1 to have some direct vasorelaxation action, cardioprotective effects in models of ischemia-reperfusion injury ...
There, Williamson was prescribed her first GLP-1 injectable, Saxenda. Six-and-a-half years later, Williamson has shed 80 pounds and moves more easily despite struggling with arthritis.
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...
GLP-1 medications are changing how millions experience food and beverages. Join us to discover the exclusive insights and science behind medication-altered taste perception and the massive market ...
DiveWire guarantees visibility for your news announcements through instant distribution to Healthcare Dive’s audience and its 141,500 newsletter subscribers for 21 days.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results